IBRX - ImmunityBio

-

$undefined

N/A

(N/A)

ImmunityBio NasdaqGS:IBRX ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.

Location: 3530 John Hopkins Court, San Diego, CA, 92121, United States | Website: https://immunitybio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

3.057B

Cash

61.59M

Avg Qtr Burn

-92.54M

Short % of Float

56.33%

Insider Ownership

74.11%

Institutional Own.

9.24%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Anktiva (N-803) + BCG Details
Cancer, Non-muscle invasive bladder cancer

Approved

Update

Anktiva (N-803) + checkpoint inhibitors Details
Non-small cell lung carcinoma, Cancer, Solid tumor/s

BLA

Submission

PD-L1 t-haNK Details
Pancreatic cancer, Cancer

Phase 2/3

Update

Anktiva (N-803) + AdHER2DC Details
Cancer, Solid tumor/s, Endometrial cancer

Phase 1/2

Initiation

CAR-NK / CD19 t-haNK Details
Cancer, Non-Hodgkin lymphoma

Phase 1

Data readout

N-803 (Anktiva), haNK and Avelumab Details
Metastatic merkel cell carcinoma, Insomnia, Mood disorders, Liver transplant, Cancer

Failed

Discontinued

hAd5-COVID-19 Details
Vaccine, COVID-19

Failed

Discontinued